Bionik Laboratories Corp. Share Price
Equities
BNKL
US09074A2087
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2023 | Bionik Laboratories Corp. Announces Executive Changes | CI |
2023 | Bionik Laboratories Corp. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
Sales 2022 | 1.27M 106M | Sales 2023 | 1.81M 151M | Capitalization | 2.8M 233M |
---|---|---|---|---|---|
Net income 2022 | -10M -834M | Net income 2023 | -4M -334M | EV / Sales 2022 | 0.17 x |
Net cash position 2022 | 1.99M 166M | Net Debt 2023 | 1.98M 166M | EV / Sales 2023 | 2.65 x |
P/E ratio 2022 |
-0.21
x | P/E ratio 2023 |
-0.56
x | Employees | 12 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Russo
CEO | Chief Executive Officer | 44 | 30/20/30 |
Michal Prywata
FOU | Founder | 33 | 08/10/08 |
Dan Gonsalves
DFI | Director of Finance/CFO | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michal Prywata
FOU | Founder | 33 | 08/10/08 |
Director/Board Member | 68 | 01/17/01 | |
Richard Russo
CEO | Chief Executive Officer | 44 | 30/20/30 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 12 | |
-2.54% | 187B | |
-1.85% | 106B | |
-4.26% | 66.9B | |
+1.39% | 49.45B | |
+16.82% | 48B | |
+4.06% | 40.84B | |
+3.49% | 26.48B | |
+0.65% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- BNKL Stock